Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms

Yaribeygi, Habib; Maleki, Mina; Sathyapalan, Thozhukat; Jamialahmadi, Tannaz; Sahebkar, Amirhossein

Abstract

Glucagon-like peptide 1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are medications used for managing diabetes, mimicking the metabolic effects of incretin hormones. Recent evidence suggests that these medications have antioxidative potentials in the diabetic milieu. The pathophysiology of most diabetic complications involves oxidative stress. Therefore, if incretin-based antidiabetic medications can alleviate the free radicals involved in oxidative stress, they can potentially provide further therapeutic effects against diabetic complications. However, the molecular mechanisms by which these medications protect against oxidative stress are not fully understood. In the current review, we discuss the potential molecular mechanisms behind these pharmacologic agents' antioxidative properties.

Citation

Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021). Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms. Oxidative Medicine and Cellular Longevity, 2021, Article 9959320. https://doi.org/10.1155/2021/9959320

• Journal Article Type: Review
• Acceptance Date: Apr 16, 2021
• Online Publication Date: Apr 28, 2021
• Publication Date: 2021
• Deposit Date: Jun 10, 2021
• Publicly Available Date: Jun 11, 2021
• Journal: Oxidative Medicine and Cellular Longevity
• Print ISSN: 1942-0900
• Publisher: Hindawi
• Peer Reviewed: Peer Reviewed
• Volume: 2021
• Article Number: 9959320
• DOI: https://doi.org/10.1155/2021/9959320
• Public URL: https://hull-repository.worktribe.com/output/3772721